NeoGenomics logo

NeoGenomics

NEO | NASDAQ
Chart Builder DCF Calculator
$15.41
-$0.61 (-3.81%)
At close: Nov 16, 2026, 4:00 PM ET
$15.41
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-3.81%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
41.7
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #477/1021 (Top 47%)

Key Statistics

Market Data

Market Cap $2.01B
1D Range
15.36 15.78
52W Range
7.19 19.91

Valuation (TTM)

PE -61.64
PB 2.51
EV/EBITDA 71.78

Valuation (NTM)

Forward PE 80.10
Forward PEG -0.55
Price Target $22.00
Loading financial charts...

Profile

NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company o...

Sector Healthcare
Employees 2,500
IPO Date Mar 16, 2004
Fiscal Year January - December

Latest News

Better Adds $43.7 Million in Volume Across Two Purchase-Focused Teams in California and the Mid-Atlantic Through NEO Home Loans Channel

3 days ago · businesswire.com

Better Adds $43.7 Million in Volume Across Two Purchase-Focused Teams in California and the Mid-Atlantic Through NEO Home Loans Channel
FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

5 days ago · globenewswire.com

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track
NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100

5 days ago · globenewswire.com

NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100
NeoGenomics to Participate in Upcoming Investor Conferences

11 days ago · businesswire.com

NeoGenomics to Participate in Upcoming Investor Conferences
NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology

15 days ago · globenewswire.com

NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology
NEO Battery Reports Fiscal Year 2027 Second Quarter Results

18 days ago · prnewswire.com

NEO Battery Reports Fiscal Year 2027 Second Quarter Results
What NeoGenomics (NEO) Said on Its Q3 Earnings Call

19 days ago · marketbeat.com

What NeoGenomics (NEO) Said on Its Q3 Earnings Call
NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus

1 month ago · newsfilecorp.com

NeOnc's Most Challenging Test Yet: Compassionate-Use Update Puts NEO100's Potential in Focus
NeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone

1 month ago · globenewswire.com

NeOnc's Boldest Test Yet: Child's Early Improvement Puts NEO100 in the Spotlight with Compassionate-Use Milestone
NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi

1 month ago · globenewswire.com

NeOnc Reports Early Clinical Improvement in First Child Treated with NEO100 Under Compassionate Use in Abu Dhabi

Earnings

Latest Earnings
Oct 28, 2026
EPS
$0.07
Beat +26.22%
REV
$209.25M
Beat +1.23%
Next Earnings
Feb 16, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$22.00
Upside
+42.76%
Buy (7)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.